Novel targets for Huntington's disease in an mTOR-independent autophagy pathway

Article metrics

Abstract

Autophagy is a major clearance route for intracellular aggregate-prone proteins causing diseases such as Huntington's disease. Autophagy induction with the mTOR inhibitor rapamycin accelerates clearance of these toxic substrates. As rapamycin has nontrivial side effects, we screened FDA-approved drugs to identify new autophagy-inducing pathways. We found that L-type Ca2+ channel antagonists, the K+ATP channel opener minoxidil, and the Gi signaling activator clonidine induce autophagy. These drugs revealed a cyclical mTOR-independent pathway regulating autophagy, in which cAMP regulates IP3 levels, influencing calpain activity, which completes the cycle by cleaving and activating G, which regulates cAMP levels. This pathway has numerous potential points where autophagy can be induced, and we provide proof of principle for therapeutic relevance in Huntington's disease using mammalian cell, fly and zebrafish models. Our data also suggest that insults that elevate intracytosolic Ca2+ (like excitotoxicity) inhibit autophagy, thus retarding clearance of aggregate-prone proteins.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Identification of autophagy-inducing drugs.
Figure 2: I1R agonists act through cAMP on Rap2B and PLC-ε to modulate autophagy.
Figure 3: The effects of L-type Ca2+ channel agonist on autophagy and mutant huntingtin aggregation are abrogated by calpain inhibition.
Figure 4: Calpain inhibition increases aggregate-prone protein clearance.
Figure 5: Calpain inhibition induces autophagy.
Figure 6: Calpain cleaves G, creating a link between the cAMP and Ca2+-calpain pathways.
Figure 7: Regulation of autophagy by calpain is mTOR independent.
Figure 8: L-type Ca2+ channel antagonists, I1R agonists, cAMP antagonists and calpain inhibitors rescue Huntington's disease phenotypes in zebrafish.

References

  1. 1

    Rubinsztein, D.C., Gestwicki, J.E., Murphy, L.O. & Klionsky, D.J. Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 6, 304–312 (2007).

  2. 2

    Klionsky, D.J. & Emr, S.D. Autophagy as a regulated pathway of cellular degradation. Science 290, 1717–1721 (2000).

  3. 3

    Rubinsztein, D.C. Lessons from animal models of Huntington's disease. Trends Genet. 18, 202–209 (2002).

  4. 4

    Gafni, J. & Ellerby, L.M. Calpain activation in Huntington's disease. J. Neurosci. 22, 4842–4849 (2002).

  5. 5

    Gafni, J. et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279, 20211–20220 (2004).

  6. 6

    Zeron, M.M. et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849–860 (2002).

  7. 7

    Tang, T.S. et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227–239 (2003).

  8. 8

    Ravikumar, B., Duden, R. & Rubinsztein, D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107–1117 (2002).

  9. 9

    Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585–595 (2004).

  10. 10

    Sarkar, S., Davies, J.E., Huang, Z., Tunnacliffe, A. & Rubinsztein, D.C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282, 5641–5652 (2007).

  11. 11

    Sarkar, S. et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101–1111 (2005).

  12. 12

    Sarkar, S. et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3, 331–338 (2007).

  13. 13

    Shibata, M. et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J. Biol. Chem. 281, 14474–14485 (2006).

  14. 14

    Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N. & Rubinsztein, D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009–25013 (2003).

  15. 15

    Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433–442 (2006).

  16. 16

    Gutierrez, M.G. et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119, 753–766 (2004).

  17. 17

    Nakagawa, I. et al. Autophagy defends cells against invading group A Streptococcus. Science 306, 1037–1040 (2004).

  18. 18

    Ogawa, M. et al. Escape of intracellular Shigella from autophagy. Science 307, 727–731 (2005).

  19. 19

    Sarbassov, D.D., Ali, S.M. & Sabatini, D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596–603 (2005).

  20. 20

    Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T. & Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295 (2004).

  21. 21

    Greenberg, D.A., Cooper, E.C. & Carpenter, C.L. Calcium channel 'agonist' BAY K 8644 inhibits calcium antagonist binding to brain and PC12 cell membranes. Brain Res. 305, 365–368 (1984).

  22. 22

    Hockerman, G.H., Peterson, B.Z., Johnson, B.D. & Catterall, W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. 37, 361–396 (1997).

  23. 23

    Mizushima, N. Methods for monitoring autophagy. Int. J. Biochem. Cell Biol. 36, 2491–2502 (2004).

  24. 24

    Kabeya, Y. et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19, 5720–5728 (2000).

  25. 25

    Osborne, N.N. Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina. Brain Res. 553, 84–88 (1991).

  26. 26

    Felsen, D. et al. Identification, localization and functional analysis of imidazoline and alpha adrenergic receptors in canine prostate. J. Pharmacol. Exp. Ther. 268, 1063–1071 (1994).

  27. 27

    Greney, H. et al. Coupling of I(1) imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline. Mol. Pharmacol. 57, 1142–1151 (2000).

  28. 28

    Kopperud, R., Krakstad, C., Selheim, F. & Doskeland, S.O. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett. 546, 121–126 (2003).

  29. 29

    Kelley, G.G., Reks, S.E., Ondrako, J.M. & Smrcka, A.V. Phospholipase C(epsilon): a novel Ras effector. EMBO J. 20, 743–754 (2001).

  30. 30

    Enserink, J.M. et al. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat. Cell Biol. 4, 901–906 (2002).

  31. 31

    Shi, G.X., Rehmann, H. & Andres, D.A. A novel cyclic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiation. Mol. Cell. Biol. 26, 9136–9147 (2006).

  32. 32

    Ster, J. et al. Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+-dependent K+ channels in cerebellar neurons. Proc. Natl. Acad. Sci. USA 104, 2519–2524 (2007).

  33. 33

    Qiao, J., Mei, F.C., Popov, V.L., Vergara, L.A. & Cheng, X. Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP. J. Biol. Chem. 277, 26581–26586 (2002).

  34. 34

    vom Dorp, F. et al. Inhibition of phospholipase C-epsilon by Gi-coupled receptors. Cell. Signal. 16, 921–928 (2004).

  35. 35

    Criollo, A. et al. Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ. 14, 1029–1039 (2007).

  36. 36

    Schell, M.J., Erneux, C. & Irvine, R.F. Inositol 1,4,5-trisphosphate 3-kinase A associates with F-actin and dendritic spines via its N terminus. J. Biol. Chem. 276, 37537–37546 (2001).

  37. 37

    Goll, D.E., Thompson, V.F., Li, H., Wei, W. & Cong, J. The calpain system. Physiol. Rev. 83, 731–801 (2003).

  38. 38

    Hayashi, S., Horie, M. & Okada, Y. Ionic mechanism of minoxidil sulfate-induced shortening of action potential durations in guinea pig ventricular myocytes. J. Pharmacol. Exp. Ther. 265, 1527–1533 (1993).

  39. 39

    Yamamoto, A. et al. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 23, 33–42 (1998).

  40. 40

    Ravikumar, B. et al. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat. Genet. 37, 771–776 (2005).

  41. 41

    Gordon, P.B., Holen, I., Fosse, M., Rotnes, J.S. & Seglen, P.O. Dependence of hepatocytic autophagy on intracellularly sequestered calcium. J. Biol. Chem. 268, 26107–26112 (1993).

  42. 42

    Sato-Kusubata, K., Yajima, Y. & Kawashima, S. Persistent activation of Gsalpha through limited proteolysis by calpain. Biochem. J. 347, 733–740 (2000).

  43. 43

    Yousefi, S. et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat. Cell Biol. 8, 1124–1132 (2006).

  44. 44

    Jackson, G.R. et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21, 633–642 (1998).

  45. 45

    Steffan, J.S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739–743 (2001).

  46. 46

    Butler, R. & Bates, G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 7, 784–796 (2006).

  47. 47

    Hucho, T.B., Dina, O.A. & Levine, J.D. Epac mediates a cAMP-to-PKC signaling in inflammatory pain: an isolectin B4(+) neuron-specific mechanism. J. Neurosci. 25, 6119–6126 (2005).

  48. 48

    Budovskaya, Y.V., Stephan, J.S., Reggiori, F., Klionsky, D.J. & Herman, P.K. The Ras/cAMP-dependent protein kinase signaling pathway regulates an early step of the autophagy process in Saccharomyces cerevisiae. J. Biol. Chem. 279, 20663–20671 (2004).

  49. 49

    Holen, I., Gordon, P.B., Stromhaug, P.E. & Seglen, P.O. Role of cAMP in the regulation of hepatocytic autophagy. Eur. J. Biochem. 236, 163–170 (1996).

  50. 50

    Orrenius, S., Zhivotovsky, B. & Nicotera, P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 4, 552–565 (2003).

Download references

Acknowledgements

We thank T. Yoshimori (Osaka University) for LC3 antibody, myc-LC3 and EGFP-LC3 constructs, N. Mizushima (Tokyo Medical and Dental University) for wild-type and knockout Atg5 MEFs, wild-type Atg5 and K130R Atg5 constructs, G. Jackson (University of California, Los Angeles) for the gmrQ120 flies, K.L. Guan (University of Michigan, Ann Arbor) for rheb construct, A. Wells (University of Pittsburgh) for constitutive active S50E m-calpain construct, J. Lomasney (Northwestern University, Chicago) for wild-type PLC-ε construct, J. de Gunzburg (Institut Curie, Paris) for dominant-negative Rap2B construct, R.F. Irvine (University of Cambridge) for cytosolic IP3 kinase A construct, M. Mizuguchi (Toyama Medical and Pharmaceutical University) for human LC3B construct, J.P. Luzio (University of Cambridge) for GFP-lgp20 construct, R. Tsien (University of California, San Diego) for mCherry construct, A.M. Tolkovsky (University of Cambridge) for EGFP-LC3 HeLa stable cells, N.P. Dantuma (Karolinska Institute, Stockholm) for UbG76V-GFP HeLa stable cells, M. Mahaut-Smith for use of the spectrophotometer, J.N. Skepper for EM, A. Roach for critical comments and A. Cordenier for technical assistance. We are grateful for the Gates Cambridge Scholarship and Hughes Hall Research Fellowship (S. Sarkar), Medical Research Council Studentships (A.W., E.K.T.), Biotechnology and Biological Sciences Research Council Career Development Award (C.J.O.'K.), Eli Lilly Pergolide Fellowship (S. Saiki), Academy of Medical Sciences–Medical Research Council Clinical Scientist Fellowship (R.A.F.), Wellcome Trust Senior Fellowship in Clinical Science (D.C.R.), Knowledge Transfer Partnership grant (Department of Trade and Industry), an MRC Programme Grant, an MRC Link Grant, European Union Framework VI (EUROSCA) and the National Institute for Health Research Biomedical Research Centre at Addenbrooke's Hospital for funding.

Author information

A.W., S. Sarkar, P.C., E.K.T., S. Saiki, F.H.S., L.J., D.P. and R.A.F. performed experiments. All authors participated in the design and analysis of various experiments. A.W., S. Sarkar and D.C.R. wrote the paper.

Correspondence to David C Rubinsztein.

Ethics declarations

Competing interests

D.P. and A.F. are employees of Summit plc and have share options in this company. A.F. and P.G. are shareholders in Summit plc. So.S., A.W., D.C.R., E.K.T., C.J.O'K. and R.A.F. are inventors on patents relating to the use of autophagy activation in various diseases.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8, Supplementary Methods and Supplementary Discussion (PDF 1644 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Williams, A., Sarkar, S., Cuddon, P. et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol 4, 295–305 (2008) doi:10.1038/nchembio.79

Download citation

Further reading